Many of you repeatedly in my mail have asked for paid calls and what they will be and all.Now as an amateur and being a social guy I would always safeguard the vested interest of investors than something else.The open blog is a place for me to give guidance.Paid blog is for the one who needs those calls and my bigtime guidance desperately.Anyways here"s an example of a paid member call and the type which I provided just couple odd months back.
btw:Broking members(Members having an online trading account with my firm) by virtue of having a lifelong association enjoys the paid calls for free.To vigil the calls of the last 3 years one can give a look to http://paidtrackrecord.blogspot.com/
Market outlook and stock tip:-Jenburkt Pharmaceuticals Ltd
Saturday, February 26, 2011
Scripscan:Jenburkt Pharmaceuticals Ltd
Code:524731
Cmp:69
Target:104
Return:50%
Duration:6-9 months
Story:.I seldom suggest pharma companies to you members as I hardly understand the business.Patent stuff,molecules,regular litigations are some daily issues which has kept me away from the sector.Jenburkt is an exceptional company and has impressed me a great deal be it the vision of the management or its well planned strategies.Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.Jenburkt pharma currently has 81 products and its variants in the domestic market while it exports around 25 products to 13 countries. It has 3 of its products currently under DPCO.As far as company`s network goes, in the domestic market its network consists of 26 Superstockists and Consignee Agents, about 1,000 Stockists and 45,000retailers.Company`s marketing team consists of 480 medical representatives and front line managers.Jenburkt's strategic decision to move up the value chain has started showing strong and positive results.The focus on long term therapies in acute and chronic ailments has begun contributing to the topline and bottom line strongly.A few brands of the company figures among the top 5 brands in their respective segments in the country and also internationally.The company has got a great dividend coverage ratio which helps under the present volatile environment.Last year it paid 3 bucks per share but with profits expected to be much higher this time a dividend of 4-5rs looks very much on.The promoters are busy accumulating shares from the market which speaks a lot about their confidence and conviction in the counter.Jenburkt is expected to post an EPS of 23 for fy12 which at present prices gives a PE of only 3.The company is also expected to be a debt free entity in near future.For a growing consistent company with a good management,decent productline,solid ROE's and ROCE,robust potential,hefty dividend yield of 7% and attractive valuation one coudnt just ask more.At 69rs its a great buy.
Todays update:The company is at 96rs up over 40% from the suggested price and looks good for even more.FII's too have recently taken a fancy to this counter.
Regards,
ARUN
I can be reached at:arunsharemarket@gmail.com
btw:Broking members(Members having an online trading account with my firm) by virtue of having a lifelong association enjoys the paid calls for free.To vigil the calls of the last 3 years one can give a look to http://paidtrackrecord.blogspot.com/
Market outlook and stock tip:-Jenburkt Pharmaceuticals Ltd
Saturday, February 26, 2011
Scripscan:Jenburkt Pharmaceuticals Ltd
Code:524731
Cmp:69
Target:104
Return:50%
Duration:6-9 months
Story:.I seldom suggest pharma companies to you members as I hardly understand the business.Patent stuff,molecules,regular litigations are some daily issues which has kept me away from the sector.Jenburkt is an exceptional company and has impressed me a great deal be it the vision of the management or its well planned strategies.Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.Jenburkt pharma currently has 81 products and its variants in the domestic market while it exports around 25 products to 13 countries. It has 3 of its products currently under DPCO.As far as company`s network goes, in the domestic market its network consists of 26 Superstockists and Consignee Agents, about 1,000 Stockists and 45,000retailers.Company`s marketing team consists of 480 medical representatives and front line managers.Jenburkt's strategic decision to move up the value chain has started showing strong and positive results.The focus on long term therapies in acute and chronic ailments has begun contributing to the topline and bottom line strongly.A few brands of the company figures among the top 5 brands in their respective segments in the country and also internationally.The company has got a great dividend coverage ratio which helps under the present volatile environment.Last year it paid 3 bucks per share but with profits expected to be much higher this time a dividend of 4-5rs looks very much on.The promoters are busy accumulating shares from the market which speaks a lot about their confidence and conviction in the counter.Jenburkt is expected to post an EPS of 23 for fy12 which at present prices gives a PE of only 3.The company is also expected to be a debt free entity in near future.For a growing consistent company with a good management,decent productline,solid ROE's and ROCE,robust potential,hefty dividend yield of 7% and attractive valuation one coudnt just ask more.At 69rs its a great buy.
Todays update:The company is at 96rs up over 40% from the suggested price and looks good for even more.FII's too have recently taken a fancy to this counter.
Regards,
ARUN
I can be reached at:arunsharemarket@gmail.com
